• Home
  • Search Results

Research Studies

UNC-Chapel Hill Lineberger Comprehensive Cancer Center

268 studies match your search
Open

Detect-ME

Do you have acid reflux, GERD, or Barrett's Esophagus? Are you having standard of care endoscopies performed? You may be able to participate in a research study testing for Barrett's Esophagus and esophageal cancer. Compensation provided.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Stomach and Esophageal)
  • Stomach, Digestion and Gut Health
Open

MRD assessment in a diverse population of patients with early-stage breast cancer -DCT

Have you diagnosed with lymph node positive early breast cancer, have received surgery, and have not received any systemic or radiation treatment prior to surgery? If so, you may be able to take part in this clinical trial which seeks to improve the treatment of early-stage breast cancer by examining ctDNA, a biomarker found in the blood that may indicate the presence of disease. This study aims to determine if ctDNA can help doctors personalize therapies leading to more effective treatment plans.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

Leukemia Treatment Study

Have you been diagnosed with Leukemia? Do you have a functioning kidney, liver, and cardiac organ? If so, you may be able to participate in a study on a new drug called LBS-007. We want to find out if it is safe for people with Leukemia. Compensation provided.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Open

Epcoritamab in Previously Treated WM

Have you been diagnosed with Waldenstrom Macroglobulinemia (WM) cancer? If so, you may be able to take part in a research study to determine if epcoritamab can be used to treat patients with previously treated WM.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Lymphoma)
Coming Soon

Safety and Efficacy of Belantamab Monotherapy and in Combination Treatments for the Treatment of Multiple Myeloma

The purpose of this study is to determine whether a new investigational combination of drugs, that contains belantamab mafodotin with belantamab, will be as effective, and more tolerable, compared to belantamab mafodotin alone in participants with multiple myeloma that has become active again after at least three prior lines of treatment.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Multiple Myeloma)
Open

C4391024: "AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)"

Have you been diagnosed hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, locally advanced or metastatic breast cancer, and have not received any systemic anti-cancer treatment for the disease. The study will explore the effects of the study drug PF-07220060 plus letrozole and if it is more effective compared to currently approved drugs (palbociclib, abemaciclib, or ribociclib) in combination with letrozole. This study is different from your regular medical care. The purpose of your regular medical care is to manage or improve your health, but the purpose of research is to gather information to advance science and medicine and does not replace your regular medical care.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Breast)
Coming Soon

Tirzepatide in Obesity-Driven Endometrial Cancer

To determine the anti-proliferative effect of tirzepatide on the endometrium of endometrial cancer (EC) patients .

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Uterine (endometrial))
Open

QuantifyHER

This trial seeks to enroll patients diagnosed with HER2-negative (HER2- low or HER2-0)- MBC who are starting treatment with T-DXd. The purpose is to determine if the test used for HER2+ MBC also works for HER2-low MBC. By participating in this trial, you are contributing to information that may improve the care of future patients with HER2-negative (HER2- low or HER2-0)- MBC. This trial does not require additional biopsies. Only tissue left over from a standard-of-care procedure will be used. The study team will access your medical record to review routine imaging test results as well as track your response to your treatment. Your breast cancer care will be managed by your oncologist, and you won't need to interact with the study team for direct care. No extra visits with the study team are required, except possibly for the initial enrollment.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

Gene Therapy Study for CD19 Positive Hematologic Malignancies

Do you have a CD19 positive hematologic malignancy? Has your disease returned after responding to initial treatment (relapsed) or is not responding to treatment (refractory)? If so, you may be able to participate in this gene therapy research study.

Age & Gender
  • 13 years ~ 90 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia, Lymphoma)
Open

A Low-Dose Tamoxifen Trial for Early Breast Cancer

Do you have early-stage breast cancer that is considered low-risk by your doctor? If yes, you might be able to join a research study. In this study, we are testing if taking a lower dose of the medicine tamoxifen is a better treatment for you than the usual hormone therapy.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Breast)
  • Women's Health
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research